Welcome to our dedicated page for ILLUMINA SEC filings (Ticker: ILMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Illumina SEC filings document the company’s genomics technology business, financial results, governance and capital actions. Form 8-K reports cover quarterly and annual operating results, preliminary financial updates, share repurchase authorization, management and board changes, and Regulation FD disclosures.
The filing record also includes definitive proxy materials for annual meeting matters, director elections, compensation and shareholder voting. Material-event filings document completed acquisition activity, including the purchase of SomaLogic and Sengenics aptamer-based and functional proteomics assets, along with exhibits, common-stock repurchase disclosures and other capital-structure records.
Illumina, Inc. reports that Chief Legal Officer Scott M. Davies sold 615 shares of common stock on 2026-07-30 at $200.00 per share in a sale categorized as an open market or private transaction. The transaction was effected under a Rule 10b5-1 trading plan, and he now directly holds 20,338 shares of Illumina common stock.
Illumina, Inc. (ILMN) has a notice of proposed sale under Rule 144 for 615 shares of common stock, with an indicated aggregate market value of $119,814.30, to be sold through Morgan Stanley Smith Barney LLC on or after July 30, 2026 on NASDAQ.
The filing also lists prior sales under a Rule 10b5-1 trading plan for Scott Davies: 615 shares of common stock for $110,700.00 on June 25, 2026 and 615 shares for $98,400.00 on May 29, 2026, all related to restricted stock units issued by Illumina.
Illumina, Inc. reported second-quarter 2026 revenue of $1.16 billion, up 9.5% from Q2 2025, with rest-of-world organic revenue growth of 8.1%. GAAP operating margin was 21.1% and non-GAAP operating margin was 22.5%.
GAAP diluted EPS was $1.35 compared with $1.49 a year earlier; non-GAAP diluted EPS was $1.31 compared with $1.19. Free cash flow was $162 million versus $204 million, and cash, cash equivalents and short-term investments totaled $1.17 billion at quarter-end.
For fiscal 2026, Illumina now expects total revenue of $4.60–$4.64 billion, rest-of-world organic revenue growth greater than 5%, non-GAAP operating margin of 23.4%–23.6%, and non-GAAP diluted EPS of $5.30–$5.40.
ILLUMINA, INC. identified Michael C. Sullivan, its Chief Commercial Officer, as a reporting person for insider ownership purposes. The disclosure lists no reportable equity holdings, derivative positions, or insider transactions for Sullivan at this time.
Meister Keith A. reported acquisition or exercise transactions in this Form 4 filing.
ILLUMINA, INC. director Keith A. Meister received a stock award as part of his board compensation. He elected to take 100% of his 2026 board and committee cash retainer fees in Illumina stock, and for the second quarter 2026 this resulted in a grant of 142 shares at a reference price of $149.1868 per share. After this grant, he directly holds 6,780 shares of common stock, and additional Illumina securities are held indirectly for the accounts of private investment funds advised by Corvex Management LP, whose general partner is controlled by him.
Ullem Scott B. reported acquisition or exercise transactions in this Form 4 filing.
ILLUMINA, INC. director Scott B. Ullem reported receiving 167 shares of common stock on June 30, 2026. The shares were valued at $149.1868 per share and were granted as compensation rather than purchased on the open market.
According to the footnote, Ullem elected to receive 100% of his 2026 board and committee cash retainer fees in Illumina stock. This particular grant represents his second quarter 2026 retainer fees and is based on the volume weighted average closing price during that quarter. Following this award, he directly holds 11,030 shares of Illumina common stock.
ILLUMINA, INC.'s Chief Legal Officer Scott M. Davies completed an open-market sale of company stock. He sold 615 shares of Common Stock at a price of $180 per share. After this transaction, he directly holds 20,953 Illumina shares, so the sale represents a small portion of his overall reported position.
Illumina affiliate submitted a Form 144 to sell shares. The filing lists proposed sales tied to Performance Stock Units and Restricted Stock Units with a reported 10b5-1 sale on 05/29/2026 for 98,400 common shares. The filing records an earlier grant date of 02/21/2023.
Frances Arnold reported proposed sales of Illumina common stock via a Form 144 notice. The filing lists multiple dispositions in May–June 2026, including sales of 3,000 shares on 06/02/2026 for $484,571.70 and 5,000 shares on 05/28/2026 for $780,650.00. The filing also records restricted stock vesting of 2,000 shares on 05/21/2026 under a registered compensation plan.